Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
75.25 USD | -.--% |
|
-.--% | -.--% |
05-23 | Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney... | ![]() |
05-23 | Swiss Market Index Closes Little Changed; Julius Bär Gains | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 4.08B | - | ||
-2.46% | 23.95B | C+ | ||
+14.23% | 8.7B | B | ||
+1.47% | 8.29B | C | ||
-32.92% | 6.7B | B- | ||
+18.62% | 5.38B | B- | ||
-9.24% | 3.79B | B- | ||
-10.20% | 3.3B | B+ | ||
+7.11% | 3.19B | C | ||
+7.58% | 3.2B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GALE Stock
- GALNF Stock
- Ratings Galenica AG